Mapping the maturation of TCM as an adjuvant to radiotherapy
P. Bilha Githinji, Aikaterini Melliou, Xi Yuan, Dayan Zhang, Lian Zhang, Zhenglin Chen, Jiansong Ji, Chengying Lv, Jinhao Xu, Peiwu Qin, Dongmei Yu · 2026
Read Mapping the maturation of TCM as an adjuvant to radiotherapy by P. Bilha Githinji, Aikaterini Melliou, Xi Yuan, Dayan Zhang, Lian Zhang, Zhenglin Chen, Jiansong Ji, Chengying Lv, Jinhao Xu, Peiwu Qin, Dongmei Yu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2601-11923.txt.
Introduction
P. Bilha Githinji, Aikaterini Melliou, Xi Yuan, and a large team map how proof has grown for Traditional Chinese Medicine as an add-on to radiotherapy. Use of such add-on care in cancer wards has grown for about twenty-five years. That span is since joint cancer care took formal shape.
Their sum traces how the proof base has matured over that time. Such a map can show which uses rest on firm trials and which rest on thin proof. It can guide new trials to gaps. It also helps clinics weigh claims with care.
Catalog record
| CREATOR | P. Bilha Githinji, Aikaterini Melliou, Xi Yuan, Dayan Zhang, Lian Zhang, Zhenglin Chen, Jiansong Ji, Chengying Lv, Jinhao Xu, Peiwu Qin, Dongmei Yu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 63 KB |
| VERSION | 1.0 |
| LICENSE | http://creativecommons.org/licenses/by/4.0/ |
| RIGHTS | CC BY |
| SOURCE | arXiv |
Source: https://arxiv.org/abs/2601-11923
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Mapping the maturation of TCM as an adjuvant to radiotherapy P. Bilha Githinji, Aikaterini Melliou, Xi Yuan, Dayan Zhang, Lian Zhang, Zhenglin Chen, Jiansong Ji, Chengying Lv, Jinhao Xu, Peiwu Qin, Dongmei Yu Abstract The integration of complementary medicine into oncology represents a paradigm shift that has seen to increasing adoption of Traditional Chinese Medicine (TCM) as an adjuvant to radiotherapy. About twenty-five years since the formal institutionalization of integrated oncology, it is opportune to synthesize the trajectory of evidence for TCM as an adjuvant to radiotherapy. Here we conduct a large-scale analysis of 69,745 publications (2000 - 2025), emerging a cyclical evolution defined by coordinated expansion and contraction in publication output, international collaboration, and funding commitments that mirrors a define-ideate-test pattern. Using a theme modeling workflow designed to determine a stable thematic structure of the field, we identify five dominant thematic axes - cancer types, supportive care, clinical endpoints, mechanisms, and methodology - that signal a focus on patient well-being, scientific rigor and mechanistic exploration. Cross-theme integration of TCM is patient-centered and systems-oriented. Together with the emergent cycles of evolution, the thematic structure demonstrates progressive specialization and potential defragmentation of the field or saturation of existing research agenda. The analysis points to a field that has matured its current research agenda and is likely at the cusp of something new. Additionally, the field exhibits positive reporting of findings that is homogeneous across publication types, thematic areas, and the cycles of evolution suggesting a system-wide positive reporting bias agnostic to structural drivers. Keywords TCM \cdot Radiotherapy \cdot Integrative Oncology \cdot Global Landscape 1 Introduction Traditional Chinese Medicine (TCM) is increasingly an important adjunctive therapy alongside radiotherapy within integrative oncology practice and research, and is frequently utilized by patients for relief from cancer- and treatment-related symptom burden 1 , 2 , 3 . Over the past quarter-century, the literature has expanded to encompass a growing body of evidence addressing treatment tolerance and adherence, symptom burden, and patient-reported outcomes and experiences alongside preclinical and mechanistic investigations 1 , 2 , 3 , 4 . This maturation creates a timely opportunity for consolidation and macro-level synthesis of the field’s intellectual foundation and temporal dynamics, informing future research directions and evidence synthesis priorities. To conduct such a synthesis, advances in computational bibliometric analysis and natural language processing (NLP) text analysis enable fine-grained characterization of large-scale research landscapes and facilitate automated semantic interrogation of scientific texts across large corpora. One such opportunity for semantic-based analysis concerns how results are framed and communicated (rhetorical framing of results), offering a lens on field-level optimism and potential systemic incentives and structural drivers of reporting behavior 5 , 6 , 7 . Conversely, inherent stochasticity in these computational tools and particularly in topic modeling or clustering-based theme extraction, can lead to inconsistency in inferred thematic structures, hindering reproducibility and complicating interpretability 8 . In this study, we analyze a large corpus of 69,745 publications examining TCM as an adjunctive therapy to radiotherapy over the past twenty-five years. We construct a stable latent thematic structure of the field through a 98.5% Jaccard similarity-based convergence across multiple topic-modeling instantiations that employ different text embedding models and clustering hyperparameters for term grouping. Furthermore, utilizing a large language model (LLM)-based pipeline for extraction and classification, we examine the rhetorical framing of results reported in the abstracts. Specific contributions of this report include • We map the field across a wider range of publication types and cancer types with a corpus of 69,745 publications. • We empirically emerge a cyclic pattern of evolution in the field that is based on congruence of growth patterns across multiple activity indicators concerning publication output, collaboration breadth, and funding acknowledgments. This cyclic pattern is further evidenced in the the thematic structure and, together, these two empirical results portray a field that appears to follow a define-ideate-test pattern so far. From the observed pattern, the years 2025 - 2027 could be at the cusp of the next interval of reflection that precedes a multi-year period of expansion. • We find that while there is rhetorical positive reporting of findings within abstract texts in the field, this reporting bias is homogeneous across publication types, thematic areas, and the identified cycles of evolution. • Methodologically, we establish a stable, convergent thematic structure of the field. By employing modern NLP embedding for topic modeling, operating on the entire abstract document, and converging topic modeling outputs from multiple algorithmic ensembles of embedding models and clustering hyperparameters, we identify a consensus thematic structure that has richer semantic breadth than is usually achievable with keywords analysis, and that is determined with a Jaccard similarity threshold of 98.5%. 2 Background Radiotherapy is a central component of modern oncology, fulfilling definitive, adjuvant and palliative roles across a wide range of cancers, and featuring in the treatment course of more than half of all cancer patients 9 . However, radiotherapy is also associated with treatment-related toxicity. Patients commonly experience cancer-related and radiation-induced effects like fatigue, nausea and vomiting, dermatitis, pain, sleep disturbance, anxiety, and depressive symptoms, with some adverse effects persisting months or years after treatment 9 , 2 , 1 , 4 .These complications can markedly reduce quality of life and lead to treatment interruptions, compromising clinical outcomes. The positioning of TCM as a complementary or adjunctive therapy rather than an alternative modality in oncology was driven by sustained patient demand and the institutionalization of integrative oncology as a clinical and research discipline 2 , 4 , 10 . Integrative oncology provided a conceptual, clinical and organizational framework through which traditional practices could be systematically defined, evaluated using biomedical research methods, and clinically integrated alongside conventional cancer treatments 2 , 4 , 11 , 12 . Its central aim is to combine conventional and complementary approaches in a manner that prioritizes safety, clinical effectiveness, and patient-centered care 4 , 11 , 12 . In TCM, syndrome and the modern definition of disease are conceptualized as patterns (zheng) of systemic disharmony, and treatment aims at regulating qi, blood, yin-yang balance and organ systems. TCM represents a major component of complementary medicine within integrative oncology, and includes modalities such as Chinese herbal medicine (formula-based prescriptions), TCM dietary therapy (shiliao), acupuncture and moxibustion, and qigong (mind-body exercise) 13 , 14 . Recent bibliometric studies mapping TCM-related research in oncology have restricted their scope to specific cancer types, individual TCM modalities or narrowly defined clinical or biological contexts. Cancer-specific bibliometric analyses commonly identify mechanism-focused topics as dominant themes. In lung cancer, anticancer mechanisms and computational and systems-level approaches such as network pharmacology and molecular docking feature, while liver cancer studies highlight apoptosis and signaling pathways such as NF- \kappa B 15 , 16 . Similarly, context-constrained analyses such as those examining immune modulation or gut microbiota regulation, discover themes on pharmacodynamics, immune checkpoints, signaling pathway regulation, apoptosis, short-chain fatty acids, and computational multi-omics techniques 17 , 18 , 19 . Conversely, bibliometric analyses on clinical application of individual TCM modalities in supportive or adjunctive care report patient and outcome-centered themes. For example, acupuncture-focused analyses identify themes regarding management of treatment-related or cancer-related symptoms (e.g. pain, fatigue, sleep disturbance) and improvement in health-related quality of life of the patient 20 , 21